The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology.
暂无分享,去创建一个
Elaine Lyon | Jill Hagenkord | Milena Cankovic | Loren Joseph | Samuel Caughron | Pranil Chandra | Rajyasree Emmadi | Stephanie Hallam | Kay E. Jewell | Roger D. Klein | Victoria M. Pratt | Paul G. Rothberg | Robyn L. Temple-Smolkin | E. Lyon | R. Klein | P. Rothberg | S. Hallam | R. Emmadi | V. Pratt | P. Chandra | J. Hagenkord | Samuel K. Caughron | K. Jewell | M. Cankovic | Loren J. Joseph | Pranil K. Chandra
[1] V. Miller,et al. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein , 2014, Journal of Hematology & Oncology.
[2] J. Lentz,et al. Usher Syndrome Type 2 , 2016, Definitions.
[3] A. Marchevsky,et al. Evidence-based pathology: systematic literature reviews as the basis for guidelines and best practices. , 2015, Archives of Pathology & Laboratory Medicine.
[4] Ashish Choudhary,et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. , 2013, The Journal of molecular diagnostics : JMD.
[5] E. Alexander,et al. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. , 2014, Thyroid : official journal of the American Thyroid Association.
[6] D. Lipson,et al. Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary , 2014, Case Reports in Oncology.
[7] H. Elphick,et al. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis , 2013, Drug design, development and therapy.
[8] Mary B. Daly,et al. BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer , 2013 .
[9] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[10] R. Schilsky,et al. Molecular markers to individualize adjuvant therapy for colon cancer , 2010, Nature Reviews Clinical Oncology.
[11] Suk-Kyeong Kim,et al. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma , 2015, Clinical endocrinology.
[12] P. Shannon,et al. Exome sequencing identifies the cause of a Mendelian disorder , 2009, Nature Genetics.
[13] P. Stephens,et al. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. , 2014, Clinical breast cancer.
[14] W. Burke,et al. Debating Clinical Utility , 2010, Public Health Genomics.
[15] Judy H. Cho,et al. Expanded genetic screening panel for the Ashkenazi Jewish population , 2015, Genetics in Medicine.
[16] P. Kowey,et al. Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients? , 2014, World journal of cardiology.
[17] G. Lyman,et al. Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology , 2015, Genetics in Medicine.
[18] Steven J. M. Jones,et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors , 2010, Genome Biology.
[19] Mary Brophy,et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. , 2016, Journal of clinical epidemiology.
[20] E. Deeks. Ivacaftor: A Review of Its Use in Patients with Cystic Fibrosis , 2013, Drugs.
[21] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[22] A. Guttmacher,et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia , 2009, Journal of Medical Genetics.
[23] Simona Soverini,et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. , 2011, Blood.
[24] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[25] K. Klinger,et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening , 2001, Genetics in Medicine.
[26] David C. Atkins,et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Austin,et al. MARFAN SYNDROME , 2018, Cassidy and Allanson's Management of Genetic Syndromes.
[28] Magalie S Leduc,et al. Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.
[29] Ken Chen,et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. , 2011, JAMA.
[30] Amy Maxmen,et al. Exome Sequencing Deciphers Rare Diseases , 2011, Cell.
[31] A. Chapelle. The Incidence of Lynch Syndrome , 2004, Familial Cancer.
[32] Marc S. Williams,et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.
[33] H. Hakonarson,et al. Whole-genome DNA/RNA sequencing identifies truncating mutations in RBCK1 in a novel Mendelian disease with neuromuscular and cardiac involvement , 2013, Genome Medicine.
[34] H. Hakonarson,et al. Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency. , 2011, American journal of human genetics.
[35] R. Pai,et al. Preoperative GNAS and KRAS Testing in the Diagnosis of Pancreatic Mucinous Cysts , 2014, Clinical Cancer Research.
[36] Rena A. Godfrey,et al. The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases , 2011, Genetics in Medicine.
[37] J. Blay,et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.
[38] Elaine Lyon,et al. The Evolving Role of the Laboratory Professional in the Age of Genome Sequencing: A Vision of the Association for Molecular Pathology. , 2015, The Journal of molecular diagnostics : JMD.
[39] David B. Matchar,et al. Chapter 1: Introduction to the Methods Guide for Medical Test Reviews , 2012, Journal of general internal medicine.
[40] Jonathan S Berg,et al. Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. , 2015, American journal of human genetics.
[41] Michael F. Wangler,et al. De novo truncating mutations in AHDC1 in individuals with syndromic expressive language delay, hypotonia, and sleep apnea. , 2014, American journal of human genetics.
[42] I. Schmidt-Wolf,et al. Hairy cell leukemia: short review, today's recommendations and outlook , 2014, Blood Cancer Journal.
[43] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[45] I. Yang,et al. Molecular staging for survival prediction of colorectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Magalie S Leduc,et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.
[47] Gil McVean,et al. The 100,000 Genomes Project Protocol , 2017 .
[48] Alfonso Valencia,et al. Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment , 2014, Clinical Cancer Research.
[49] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[50] BlueCross BlueShield. Special report: exome sequencing for clinical diagnosis of patients with suspected genetic disorders. , 2013, Technology Evaluation Center Assessment Program. Executive summary.
[51] J. Mahlangu,et al. Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[52] Philipp W. Raess,et al. The Role of Molecular Pathology in the Diagnosis of Cutaneous Lymphomas , 2012, Pathology research international.
[53] J. Dungan. Association Between Carrier Screening and Incidence of Cystic Fibrosis , 2010 .
[54] Fabio Mosca,et al. Prevalence of the Congenital Long-QT Syndrome , 2009, Circulation.
[55] James C. Mullikin,et al. Exome sequencing: the sweet spot before whole genomes , 2010, Human molecular genetics.
[56] M. Greene,et al. A major step forward for BRCA1/2-related cancer risk management. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] M. Bibbo,et al. The added value of molecular testing in small pancreatic cysts. , 2010, JOP : Journal of the pancreas.
[58] M. McDevitt,et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[59] A. Tefferi,et al. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.
[60] R. Seethala,et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next‐generation sequencing assay , 2014, Cancer.
[61] V. Eysselein,et al. Fluid genetic analyses predict the biological behavior of pancreatic cysts: three-year experience. , 2014, JOP : Journal of the pancreas.
[62] Robert Brian Jenkins,et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[63] B. Harper. Huntington Disease , 2005, Journal of the Royal Society of Medicine.
[64] Shivang Doshi,et al. Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis , 2016, The Journal of molecular diagnostics : JMD.
[65] R. Sullivan,et al. Resistance to BRAF-targeted therapy in melanoma. , 2013, European journal of cancer.
[66] M Hummel,et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.
[67] K. Owzar,et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. , 2005, The New England journal of medicine.
[68] Darya Chudova,et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. , 2012, The New England journal of medicine.
[69] Quantifying the health benefits of genetic tests: A clinical perspective , 2006, Genetics in Medicine.
[70] J. Fagin,et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] Michael B Atkins,et al. Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.
[72] M. HershmanJerome,et al. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. , 2014 .
[73] M. Nikiforova,et al. New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers , 2013, Clinical Cancer Research.
[74] G. Giaccone,et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, Archives of pathology & laboratory medicine.
[75] Jeff Shrager,et al. Rapid learning for precision oncology , 2014, Nature Reviews Clinical Oncology.
[76] Alan F. Scott,et al. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..
[77] D. Aisner,et al. A Suggested Molecular Pathology Curriculum for Residents: A Report of the Association for Molecular Pathology. , 2016, The Journal of molecular diagnostics : JMD.
[78] Rosalind Eeles,et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.
[79] Alexander F. Wilson,et al. Research in Genomic Medicine the Clinseq Project: Piloting Large-scale Genome Sequencing for Material Supplemental , 2009 .
[80] Roberta A Pagon,et al. GeneTests: an online genetic information resource for health care providers. , 2006, Journal of the Medical Library Association : JMLA.
[81] Jodi B. Segal,et al. Chapter 3: Choosing the Important Outcomes for a Systematic Review of a Medical Test , 2012, Journal of general internal medicine.
[82] Nicola D. Roberts,et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. , 2014, Blood.
[83] Marc S. Williams,et al. US system of oversight for genetic testing: a report from the Secretary's Advisory Committee on Genetics, Health and Society. , 2008, Personalized medicine.
[84] P. Stephens,et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.